 |
12 Diseases |  |
138 Trials |
|
138 Trials |  |
3994 News |  |
| «12...28293031323334353637383940» |
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P3 trial: STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (clinicaltrials.gov) - Jun 7, 2018
P3, N=1950, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P3 trial: STEP 4: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (clinicaltrials.gov) - Jun 7, 2018
P3, N=1060, Not yet recruiting, Sponsor: Novo Nordisk A/S
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects (clinicaltrials.gov) - Apr 12, 2018
P1, N=36, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New trial, Real-world evidence, Real-world: SURE CANADA: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice (clinicaltrials.gov) - Mar 7, 2018
P=N/A, N=217, Not yet recruiting, Sponsor: Novo Nordisk A/S
- ||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: SUSTAIN 9: Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Dec 28, 2017
P3, N=302, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: SUSTAIN 10: Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes (clinicaltrials.gov) - Dec 15, 2017
P3, N=576, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: SUSTAIN 8: Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Oct 26, 2017
P3, N=784, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects (clinicaltrials.gov) - Sep 28, 2017
P1, N=36, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P4 trial: Once Weekly GLP-1 in Persons With Spinal Cord Injury (clinicaltrials.gov) - Sep 24, 2017
P4, N=30, Not yet recruiting, Sponsor: James J. Peters Veterans Affairs Medical Center
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects (clinicaltrials.gov) - Sep 20, 2017
P1, N=36, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) (clinicaltrials.gov) - Aug 31, 2017
P3, N=1050, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN 10: Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes (clinicaltrials.gov) - Jun 29, 2017
P3, N=576, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed, Combination therapy: PIONEER 10: Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jun 21, 2017
P3, N=455, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN 10: Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes (clinicaltrials.gov) - Jun 19, 2017
P3, N=576, Not yet recruiting, Sponsor: Novo Nordisk A/S
- ||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN 7: Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. (clinicaltrials.gov) - Jun 8, 2017
P3, N=1201, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN 8: Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes (clinicaltrials.gov) - May 8, 2017
P3, N=784, Recruiting, Sponsor: Novo Nordisk A/S
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN 9: Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Mar 22, 2017
P3, N=300, Recruiting, Sponsor: Novo Nordisk A/S
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) (clinicaltrials.gov) - Feb 23, 2017
P3, N=1050, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open, Combination therapy: PIONEER 10: Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes (clinicaltrials.gov) - Feb 7, 2017
P3, N=455, Recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P3 trial, Combination therapy: PIONEER 10: Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jan 8, 2017
P3, N=455, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||| Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
Clinical: Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Nov 9, 2016
P2, N=706, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN 7: Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. (clinicaltrials.gov) - Jul 27, 2016
P3, N=1196, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
Clinical: Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly (clinicaltrials.gov) - Apr 20, 2016
P1, N=114, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Combination therapy, Monotherapy: A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes (clinicaltrials.gov) - Feb 26, 2016
P3, N=601, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
Clinical: Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Feb 24, 2016
P2, N=706, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
Clinical: Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly (clinicaltrials.gov) - Feb 16, 2016
P1, N=114, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN 7: Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. (clinicaltrials.gov) - Feb 4, 2016
P3, N=1196, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN™ 6: Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jan 26, 2016
P3, N=3299, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN 7: Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. (clinicaltrials.gov) - Jan 6, 2016
P3, N=1196, Not yet recruiting, Sponsor: Novo Nordisk A/S
- ||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Combination therapy: SUSTAIN (clinicaltrials.gov) - Nov 27, 2015
P3, N=397, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Monotherapy: SUSTAIN: A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes (clinicaltrials.gov) - Nov 14, 2015
P3, N=308, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN™ 2: Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Nov 5, 2015
P3, N=1230, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
Clinical: Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly (clinicaltrials.gov) - Oct 22, 2015
P1, N=114, Recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
Clinical: Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Sep 24, 2015
P2, N=704, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
Clinical: Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly (clinicaltrials.gov) - Sep 23, 2015
P1, N=114, Not yet recruiting, Sponsor: Novo Nordisk A/S
- ||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN 4: Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes (clinicaltrials.gov) - Sep 10, 2015
P3, N=1089, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN™ 3: Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jul 16, 2015
P3, N=813, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
Clinical: Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jun 3, 2015
P2, N=704, Not yet recruiting, Sponsor: Novo Nordisk A/S
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes (clinicaltrials.gov) - May 26, 2015
P1, N=38, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes (clinicaltrials.gov) - May 13, 2015
P1, N=87, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN™1: Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes (clinicaltrials.gov) - May 13, 2015
P3, N=387, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects (clinicaltrials.gov) - Apr 13, 2015
P1, N=31, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Combination therapy: SUSTAIN (clinicaltrials.gov) - Mar 31, 2015
P3, N=397, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Monotherapy: SUSTAIN: A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes (clinicaltrials.gov) - Mar 10, 2015
P3, N=306, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Nov 2015
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects (clinicaltrials.gov) - Feb 5, 2015
P1, N=28, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Nov 2015 Trial primary completion date: Jul 2015 --> Apr 2015
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo (clinicaltrials.gov) - Jan 26, 2015
P1, N=30, Completed, Sponsor: Novo Nordisk A/S
Trial primary completion date: Jul 2015 --> Apr 2015 Active, not recruiting --> Completed
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Combination therapy, Monotherapy: A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jan 7, 2015
P3, N=595, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN 4: Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jan 6, 2015
P3, N=1047, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Dec 19, 2014
P1, N=82, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion: Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Dec 17, 2014
P2, N=632, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed